The MELD score improved in parallel in both groups during follow-up with 18 patients ( 64 % ) from the BMMCT group and 18 patients ( 53 % ) from the SMT group reaching the primary endpoint ( p = 0.43 ( OR 1.6 , CI 0.49-5 .4 ) in an intention to treat analysis .
